Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

WTO Price Transparency Talks Face Resistance From Developed Countries

Executive Summary

Last week the World Trade Organization’s TRIPS Council discussed transparency in medicine pricing, including R&D costs.

You may also be interested in...



Drug Pricing ‘Not Appropriate Topic’ For WTO TRIPS Council

The World Trade Organization is not the place to discuss pharmaceutical pricing, and strong intellectual property rights do not threaten access to medicines, according to EU and US delegations to the WTO.

New Italian Pricing Decree To Drive R&D Transparency

Following on from moves to push price transparency on to the global agenda, Italy is poised to pass a decree that would oblige companies to disclose public R&D funding.

EU Valletta Alliance Ups The Ante On Drug Pricing Transparency

EU countries should use a milestone World Health Organization resolution calling for more transparency on net medicine prices to help secure better access to medicine, says the Valletta group.

Related Content

Topics

UsernamePublicRestriction

Register

PS141100

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel